Vaginal Contraceptive N-9 Label Warnings Urged “As Soon As Possible” – FDA
This article was originally published in The Tan Sheet
Executive Summary
Manufacturers of vaginal contraceptives containing nonoxynol-9 should voluntarily implement proposed label warnings about increased vaginal irritation and HIV infection risk "as soon as possible," FDA advises in a 1Jan. 16 proposed rule
You may also be interested in...
FDA Allows N-9 Products To Stay On Market, Six Months For Label Compliance
Manufacturers of stand-alone, over-the-counter vaginal contraceptives and spermicidal products containing nonoxynol-9 have six months to comply with an FDA final rule requiring additional label warnings
Nonoxynol-9 Messages Conveyed By HHS Agencies Inconsistent – GAO Report
FDA will release three documents this year on the use of spermicidal lubricant nonoxynol-9 in condoms and vaginal contraceptives to protect against HIV transmission
Microbicide Trial “Condom Only”-Arm Designs To Be Reviewed By FDA Cmte.
FDA is seeking guidance from the Antiviral Drugs Advisory Committee as to whether clinical trials on topical microbicides should include a "no treatment" (condom only) arm